Vancomycin Revisited: A Reappraisal of Clinical Use

Critical Care Clinics

Volumn 24, Issue 2, 2008, Pages 393-420

  Cunha, Burke A ^a,b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; DAPTOMYCIN; GENTAMICIN; LINEZOLID; MINOCYCLINE; NAFCILLIN; RIFAMPICIN; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL ENDOCARDITIS; CENTRAL NERVOUS SYSTEM INFECTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG USE; FEBRILE NEUTROPENIA; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; CRITICAL CARE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 40849094265     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2007.12.012     Document Type: Review

References (120)

1. Kucers A., Crowe S.M., Grayson M.L., et al. Vancomycin: the use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs. 5th edition (1997), Butterworth-Heinemann, Oxford (United Kingdom) p. 763-90
2. Louria D.B., Kaminski T., and Buchman J. Vancomycin in severe staphylococcal infections. Arch Intern Med 107 (1961) 225-240
3. Cunha B.A. Vancomycin. Med Clin North Am 79 (1995) 817-831
4. Esposito A.L., and Gleckman R.A. Vancomcyin: a second look. JAMA 238 (1977) 1756-7
5. Menzies D., Goel K., and Cunha B.A. Vancomycin. Antibiotics for Clinicians 2 (1998) 97-99
6. Farber B.F., and Moellering Jr. R.C. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 23 (1983) 138-141
7. Elting L.S., Rubenstein E.B., Kurtin D., et al. Mississippi and mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 83 (1998) 2597-2607
8. Appel G.B., Given D.B., Levine L.R., et al. Vancomycin and the kidney. Am J Kidney Dis 8 (1986) 75-80
9. Mellor J.A., Kingdom J., Cafferkey M., et al. Vancomycin toxicity: a prospective study. J Antimicrob Chemother 15 (1985) 773-780
10. Nahata M.C. Lack of nephrotoxicity in pediatric patients receiving concurrent vancomycin and aminoglycoside therapy. Chemotherapy 33 (1987) 302-304
11. Goren M.P., Baker Jr. D.K., and Shenep J.L. Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children. Pediatr Infect Dis J 8 (1989) 278-282
12. Goetz M.B., and Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 32 (1993) 325-334
13. Ergur T., Onarlioglu B., Gunay Y., et al. Does vancomycin increase aminoglycoside nephrotoxicity?. Acta Paediatr Jpn 39 (1997) 422-427
14. Pauly D.J., Musa D.M., Lestico M.R., et al. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 10 (1990) 378-382
15. Rybak M.J., Albrecht L.M., Boike S.C., et al. Nephrotoxicity of vancomycin alone and with an aminoglycoside. J Antimicrob Chemother 25 (1990) 679-687
16. Ngeleka M., Beauchamp D., Tardif D., et al. Endotoxin increases the nephrotoxic potential of gentamicin and vancomycin plus gentamicin. J Infect Dis 161 (1990) 721-727
17. Rybak M.J., and Boike S.C. Monitoring vancomycin therapy. Drug Intell Clin Pharm 20 (1986) 757-761
18. Edwards D.J., and Pancorbo S. Routine monitoring of serum vancomycin concentrations: waiting for proof of its value. Clin Pharm 6 (1987) 652-654
19. Moellering Jr. R.C. Pharmacokinetics of vancomycin. J Antimicrob Chemother 14 (1984) 43-52
20. Matzke G.R., Zhanel G.G., and Guay D.R. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 11 (1986) 257-282
21. Moellering Jr. R.C., Krogstad D.J., and Greenblatt D.J. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 94 (1981) 343-346
22. Leader W.G., Chandler M.H., and Castiglia M. Pharmacokinetic optimization of vancomycin therapy. Clin Pharmacokinet 28 (1995) 327-342
23. Boffi el Amari E., Vuagnat A., Stern R., et al. High versus standard dose vancomycin for osteomyelitis. Scand J Infect Dis 36 (2004) 712-717
24. Hidayat L.K., Hsu D.I., Quist R., et al. High dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med 166 (2006) 2138-2144
25. Von Drygalski A., Curtis B.R., Bougie D.W., et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med 356 (2007) 904-910
26. Carmeli Y., Samore M.H., and Huskins C. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis. Arch Intern Med 159 (1999) 2461-2468
27. Fishbane S., Cunha B.A., Shea K.W., et al. Vancomycin-resistant enterococcus (VRE) in hemodialysis patients. Am J Infect Control 20 (1999) 461-462
28. Fridkin S.K., Lawton R., Edwards J.R., et al. Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg Infect Dis 8 (2002) 702-707
29. Fridkin S.K., Edwards J.R., Courval J.M., et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 135 (2001) 175-183
30. Kolar M., Urbanek K., Vagnerova I., et al. The influence of antibiotic use on the occurrence of vancomycin-resistant enterococci. J Clin Pharm Ther 31 (2006) 67-72
31. Cunha B.A. Antimicrobial therapy of multi-drug resistant S pneumoniae VRE & MRSA. Med Clin North Am 90 (2006) 1165-1182
32. Cunha B.A. Antibiotic essentials. 7th edition (2008), Physicians Press, Royal Oak (MI)
33. Tenover F., Biddle J., and Lancaster M. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 7 (2001) 327-332
34. Liu C., and Chambers H.F. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 47 (2003) 3040-3045
35. Cosgrove S.E., Carroll K.C., and Perl T.M. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 39 (2004) 539-545
36. Fridkin S.K., Hageman J., McDougal L.K., et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 36 (2003) 429-439
37. Wang G., Hindler J.F., Ward K.W., et al. Increased vancomycin MICs for Staphylococcus aureus. Clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 44 (2006) 3883-3886
38. Cui L., Ma K., Sato K., et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 41 (2003) 5-14
39. Cui L., Tominaga E., and Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 50 (2006) 1079-1082
40. Bell JM, Walters LJ, Turnidge JD, et al. Vancomycin hetero-resistance has a small but significant effect on the daptomycin minimum inhibitory concentration of Staphylococcus aureus [abstract D-814]. Paper presented at the 46th ICAAC. San Francisco (CA), September 27-30, 2006.
41. Sakoulas G., Alder J., Thauvin-Eliopoulos C., et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50 (2006) 1581-1585
42. Patel J.B., Jevitt L.A., Hageman J., et al. An association between a reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 42 11 (2006) 1652-1653
43. Howden B.P., Ward P.B., Charles P.G.P., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38 (2004) 521-528
44. Charles P.G., Ward P.B., Johnson P.D., et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38 (2004) 448-451
45. Moore M.R., Perdreau-Remington F., and Chambers H.F. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 47 (2003) 1262-1266
46. Howden B.P., Johnson P.D., Ward P.B., et al. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50 (2006) 3049-3057
47. Wong S.S., Ng T.K., Yam W.C., et al. Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin. Diagn Microbiol Infect Dis 36 (2000) 261-268
48. Fridkin S.K. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 32 (2001) 108-115
49. Bouza E., Burillo A., and Munoz P. Antimicrobial therapy of Clostridium difficile-associated diarrhea. Med Clin North Am 90 (2006) 1141-1163
50. Cunha B.A., and Klein N.C. Vancomycin. In: Yoshikawa T. (Ed). Antibiotics in the elderly (1994), Marcel Dekker, New York p. 311-22
51. Gump D.W. Vancomycin for treatment of bacterial meningitis. Rev Infect Dis 3 (1981) 289-292
52. Nagl M., Neher C., Hager J., et al. Bactericidal activity of vancomycin in cerebrospinal fluid. Antimicrob Agents Chemother 43 (1999) 1932-1934
53. Skhirtladze K., Hutschala H., Fleck T., et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 50 (2006) 1372-1375
54. Massias L., Dubois C., de Lentdecker P., et al. Penetration of vancomycin in uninfected sternal bone. Antimicrob Agents Chemother 36 (1992) 2539-2541
55. Ackerman B.H., and Vannier A.M. Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob Chemother 29 (1992) 460-461
56. Cunha B.A., Deglin J., Chow M., et al. Pharmacokinetics of vancomycin in patients undergoing chronic hemodialysis. Rev Infect Dis 3 (1981) 269-272
57. DelDot M.E., Lipman J., and Tett S.E. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol 58 (2004) 259-268
58. Lutsar I., McCracken Jr. G.H., and Friedland I.R. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 27 (1998) 1117-1127
59. Byl B., Jacobs F., Wallemacq P., et al. Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion. Antimicrob Agents Chemother 47 (2003) 2015-2017
60. Cruciani M., Gatti G., Lazzarini L., et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 38 (1996) 865-869
61. Cruciani M., Gatti G., Lazzarini L., et al. Penetration of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 38 (1996) 865-869
62. Rybak M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 18 (1994) 544-546
63. Zimmermann A.E., Katona B.G., and Plaisance K.I. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 15 (1995) 85-91
64. James J.K., Palmer S.M., Levine D.R., et al. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 40 (1996) 696-700
65. Kralovicov K., Spanik S., Halko J., et al. Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients?. J Chemother 9 (1997) 420-426
66. Masur H., Francioli P., Ruddy M., et al. Vancomycin serum levels and toxicity in chronic haemodialysis patients with Staphylococcus aureus bacteremia. Clin Nephrol 20 (1983) 85-88
67. Andres I., Lopez R., Pou L., et al. Vancomycin monitoring: one or two serum levels?. Ther Drug Monit 19 (1997) 614-619
68. Sayers J.F., and Shimasaki R. Routine monitoring of serum vancomycin concentrations: The answer lies in the middle. Clin Pharm 7 (1988) 18
69. Moellering Jr. R.C. Monitoring serum vancomycin levels: climbing the mountain because it is there?. Clin Infect Dis 18 (1994) 544-546
70. Rodvold K.A., Zokufa H., and Rotschafer J.C. Routine monitoring of serum vancomycin concentrations: Can waiting be justified?. Clin Pharm 6 (1987) 655-658
71. Freeman C.D., Quintiliani R., and Nightingale C.H. Vancomycin therapeutic drug monitoring: Is it necessary. Ann Pharmacother 27 (1993) 594-598
72. Saunders N.J. Vancomycin administration and monitoring reappraisal. J Antimicrob Chemother 36 (1995) 279-282
73. Karam C.M., McKinnon P.S., Neuhauser M.M., et al. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy 19 (1999) 257-266
74. Darko W., Medicis J.J., Smith A., et al. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy 23 (2003) 643-650
75. Cantu T.G., Yamanaka-Yuen N.A., and Lietman P.S. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 18 (1994) 533-543
76. Cunha B.A. Vancomycin serum levels: unnecessary, unhelpful, and costly. Antibiotics for Clinicians 8 (2004) 273-277
77. Cunha B.A., Mohan S.S., Hamid N., et al. Cost ineffectiveness of serum vancomycin levels. Eur J Clin Microbiol Infect Dis 13 (2007) 509-511
78. Allegaert K., and van den Anker J.N. Predictability of vancomycin pharmacokinetics in neonates. Eur J Clin Microbiol Infect Dis 26 (2007) 847-848
79. Cunha B.A. Clinical manifestations and antimicrobial therapy of methicillin resistant Staphylococcus aureus (MRSA). Clin Microbiol Infect 11 (2005) 33-42
80. Alder J.D. Staphylococcus aureus: antibiotic resistance and antibiotic selection. Antibiotics for Clinicians 10 S1 (2006) 19-24
81. Krol V., Cunha B.A., Schoch P.E., et al. Empiric gentamicin and vancomycin therapy for bacteremias in chronic dialysis outpatient units in the era of antibiotic resistance. J Chemother 18 (2006) 490-493
82. Quale J., Landman D., Saurina G., et al. Manipulation of hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 23 (1996) 1020-1025
83. Saribas S., and Bagdatli Y. Vancomycin tolerance in enterococci. Chemotherapy 50 (2004) 250-254
84. Watanakunakorn C. Antibiotic-tolerant Staphylococcus aureus. J Antimicrob Chemother 4 (1978) 561-568
85. Cunha B.A., Mickail N., and Eisenstein L. E faecalis vancomycin sensitive enterococci (VSE) bacteremia unresponsive to vancomycin successfully treated with high dose daptomycin. Heart Lung 36 (2007) 456-461
86. Hussain F.M., Boyle-Vavra S., Shete P.B., et al. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J Infect Dis 186 (2002) 661-667
87. Sakoulas G., Moise-Broder P.A., Schentag J.J., et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42 (2004) 2398-2402
88. Schwaber M.J., Wright S.B., Carmeli Y., et al. Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg Infect Dis 9 (2003) 657-664
89. Srinivasan A., Dick J.D., and Perl T.M. Vancomcyin resistance in staphylococci. Clin Microbiol Rev 15 (2002) 430-438
90. Walsh T.R., and Howe R.A. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol 56 (2002) 657-675
91. Wooton M., Walsh T.R., and Macgowan A.P. Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Cheomther 49 (2005) 3982-3983
92. Ward P.B., Johnson P.D., Grabsch E.A., et al. Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med J Aust 175 (2001) 480-483
93. Wooten M., MacGowan A.P., and Walsh T.R. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and Heterogenous GISA isolates. Antimicrob Agents Chemother 50 (2006) 4195-4197
94. Burillo A., and Bouza E. Epidemiology of MSSA and MRSA: colonization and infection. Antibiotics for Clinicians 10 S1 (2006) 3-10
95. Kim S.H., Park W.B., Lee K.D., et al. Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. Clin Infect Dis 37 (2003) 794-799
96. Evans M., and Finch R. Approach to staphylococcal central IV line infections and bacteremias. Antibiotics for Clinicians 10 S1 (2006) 25-28
97. Cunha B.A. Persistent S aureus bacteremia: clinical pathway for diagnosis & treatment. Antibiotics for Clinicians 10 S1 (2006) 39-46
98. Chang F.Y., Peacock Jr. J.E., Musher D.M., et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 82 (2003) 333-339
99. Lodise T.P., McKinnon P.S., Swiderski L., et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 36 (2003) 1418-1423
100. Rotun S.S., Mcmath V., Schoonmaker D.J., et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 5 (1999) 147-149
101. Cunha B.A. IV line infections. In: Cunha B.A. (Ed). Infectious diseases in critical care medicine. 2nd edition (2007), Informa Healthcare, New York
102. Morris A.J., and Bilinsky R.T. Prevention of staphylococcal shunt infections by continuous vancomycin prophylaxis. Am J Med Sci 262 (1971) 87-92
103. Eykyn S., Phillips I., and Evans J. Vancomycin for staphylococcal shunt site infections in patients on regular haemodialysis. Br Med J 3 (1970) 8-82
104. Tofte R.W., Solliday J., Rotschafer J., et al. Staphylococcus aureus infection of dialysis shunt: absence of synergy with vancomycin and rifampin. South Med J 74 (1981) 612-616
105. Cunha B.A., Gill M.V., and Lazar J. Acute infective endocarditis. Infect Dis Clin North Am 10 (1996) 811-834
106. Cunha B.A. MSSA/MRSA acute bacterial endocarditis (ABE): clinical pathway for diagnosis & treatment. Antibiotics for Clinicians 10 S1 (2006) 29-34
107. Brusch J.L. Infective endocarditis (2007), Informa Healthcare, New York p. 143-272
108. Picazo J.J. Association for Health Research and Development (ACINDES). Management of the febrile neutropenic patient. Int J Antimicrob Agents 2 S1 (2005) S120-S122
109. Cunha B.A. Clinical approach to antibiotic therapy in the penicillin allergic patient. Med Clin North Am 90 (2006) 1257-1264
110. Bliziotis I.A., Ntziora F., Lawrence K.R., et al. Rifampin as adjuvant treatment of gram-positive bacterial infections: a systemic review of comparative clinical trials. Eur J Clin Microbiol Infect Dis 26 (2007) 849-856
111. Gentry C.A., Rodvold K.A., Novack R.M., et al. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 17 (1977) 990-997
112. Geraci J.E., and Wilson W.R. Vancomycin therapy for infective endocarditis. Rev Infect Dis 3 Suppl (1981) S520-58
113. Small P.M., and Chambers H.F. Vancomycin for Staphylococcal aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 34 (1990) 1227-1231
114. Lee D.G., Chun H.S., Yim D.S., et al. Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model. Antimicrob Agents Chemother 47 (2003) 3768-3773
115. Levine D.P., Fromm B.S., and Reddy B.R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 115 (1991) 674-680
116. Shelburne S.A., Musher D.M., Hulten K., et al. In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob Agents Chemother 48 (2004) 4016-4019
117. Cha R., Brown W.J., and Ryback M.J. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 47 (2003) 3960-3963
118. Kirst H.A., Thompson D.G., and Nicas T.I. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 42 (1998) 1303-1304
119. Stevens D.L. The role of vancomycin in the treatment paradigm. Clin Infect Dis 42 (2006) S51-S57
120. Pope S.D., and Roecker A. Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections. Expert Opin Pharmacother 8 (2007) 1245-1261